On September 5, 2022 Tyra Biosciences, Inc. ( Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, reported that the Company will be presenting preclinical data on TYRA-300 during a poster session at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) 2022 Congress, being held in person September 9-13, 2022 in Paris, France (Press release, Tyra Biosciences, SEP 5, 2022, View Source [SID1234619004]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We believe the preclinical results being presented at the ESMO (Free ESMO Whitepaper) Congress showcase the enhanced anti-tumor activity and selectivity of TYRA-300 as compared to other agents in the class," said Todd Harris, CEO of TYRA. "These encouraging data support the advancement of TYRA-300 into the clinic, and we look forward to initiating our SURF301 Phase 1/2 study in the near term."
Details of the poster presentation are as follows:
Title: TYRA-300: FGFR3 selective and gatekeeper agnostic
Presenter: Jacqueline Starrett
Date: Monday, September 12, 2022
Session: Developmental therapeutics
Presentation Number: 462P
Regular abstracts will be published on the ESMO (Free ESMO Whitepaper) website on September 5, 2022. The poster presentation on TYRA-300 will be made available on the TYRA website under the "For Investors" section on September 12, 2022.
About TYRA-300
TYRA-300 is the Company’s lead precision oncology program generated from TYRA’s proprietary SNÅP drug discovery platform. TYRA-300 is an FGFR3-selective inhibitor designed to be agnostic to the gatekeeper mutation and has demonstrated less hyperphosphatemia mediated by FGFR1 inhibition than pan-FGFR inhibitors in preclinical models. In July 2022, the U.S. Food and Drug Administration (FDA) cleared TYRA to proceed with its Phase 1/2 SURF301 clinical study of TYRA-300 under its Investigational New Drug application (IND), in patients with metastatic urothelial carcinoma of the bladder and urinary tract. SURF301 is a two-part study designed to determine the optimal and maximum tolerated doses (MTD) and the recommended Phase 2 dose (RP2D) of TYRA-300.